Selected research
Market Analysis & Forecast
Global Autoimmune Drugs Market Analysis and Forecast 2026-2032
Market perspective
The global Autoimmune Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Autoimmune Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Autoimmune Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Autoimmune Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Autoimmune Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global manufacturers of Autoimmune Drugs include Biogen, AbbVie, Amgen, Baxter, GSK, Pfizer, Eli Lilly, Roche and Johnson & Johnson, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Autoimmune Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Autoimmune Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Autoimmune Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Autoimmune Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Autoimmune Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Autoimmune Drugs sales, projected growth trends, production technology, application and end-user industry.
Autoimmune Drugs Segment by Company
Biogen
AbbVie
Amgen
Baxter
GSK
Pfizer
Eli Lilly
Roche
Johnson & Johnson
Autoimmune Drugs Segment by Type
Psoriasis
Inflammatory Bowel Disease (IBD)
Systemic Lupus Erythematosus (SLE)
Ankylosing Spondylitis (AS)
Rheumatoid Arthritis (RA)
Multiple Sclerosis (MS)
Autoimmune Drugs Segment by Application
Hospitals
Homecare
Specialty Clinics
Autoimmune Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Autoimmune Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Autoimmune Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Autoimmune Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Autoimmune Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Autoimmune Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Autoimmune Drugs sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Psoriasis
- Inflammatory Bowel Disease (IBD)
- Systemic Lupus Erythematosus (SLE)
- Ankylosing Spondylitis (AS)
- Rheumatoid Arthritis (RA)
- Multiple Sclerosis (MS)
Applications
- Hospitals
- Homecare
- Specialty Clinics
Companies covered
- Biogen
- AbbVie
- Amgen
- Baxter
- GSK
- Pfizer
- Eli Lilly
- Roche
- Johnson & Johnson
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Autoimmune Drugs Market by Type
- 1.2.1 Global Autoimmune Drugs Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Psoriasis
- 1.2.3 Inflammatory Bowel Disease (IBD)
- 1.2.4 Systemic Lupus Erythematosus (SLE)
- 1.2.5 Ankylosing Spondylitis (AS)
- 1.2.6 Rheumatoid Arthritis (RA)
- 1.2.7 Multiple Sclerosis (MS)
- 1.3 Autoimmune Drugs Market by Application
- 1.3.1 Global Autoimmune Drugs Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Hospitals
- 1.3.3 Homecare
- 1.3.4 Specialty Clinics
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Autoimmune Drugs Market Dynamics
- 2.1 Autoimmune Drugs Industry Trends
- 2.2 Autoimmune Drugs Industry Drivers
- 2.3 Autoimmune Drugs Industry Opportunities and Challenges
- 2.4 Autoimmune Drugs Industry Restraints
3 Global Market Growth Prospects
- 3.1 Global Autoimmune Drugs Revenue Estimates and Forecasts (2021-2032)
- 3.2 Global Autoimmune Drugs Revenue by Region
- 3.2.1 Global Autoimmune Drugs Revenue by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Autoimmune Drugs Revenue by Region (2021-2026)
- 3.2.3 Global Autoimmune Drugs Revenue by Region (2027-2032)
- 3.2.4 Global Autoimmune Drugs Revenue Market Share by Region (2021-2032)
- 3.3 Global Autoimmune Drugs Sales Estimates and Forecasts 2021-2032
- 3.4 Global Autoimmune Drugs Sales by Region
- 3.4.1 Global Autoimmune Drugs Sales by Region: 2021 VS 2025 VS 2032
- 3.4.2 Global Autoimmune Drugs Sales by Region (2021-2026)
- 3.4.3 Global Autoimmune Drugs Sales by Region (2027-2032)
- 3.4.4 Global Autoimmune Drugs Sales Market Share by Region (2021-2032)
- 3.5 US & Canada & Mexico
- 3.6 Europe
- 3.7 China
- 3.8 Asia (Excluding China)
- 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
- 4.1 Global Autoimmune Drugs Revenue by Manufacturers
- 4.1.1 Global Autoimmune Drugs Revenue by Manufacturers (2021-2026)
- 4.1.2 Global Autoimmune Drugs Revenue Market Share by Manufacturers (2021-2026)
- 4.1.3 Global Autoimmune Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Autoimmune Drugs Sales by Manufacturers
- 4.2.1 Global Autoimmune Drugs Sales by Manufacturers (2021-2026)
- 4.2.2 Global Autoimmune Drugs Sales Market Share by Manufacturers (2021-2026)
- 4.2.3 Global Autoimmune Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025
- 4.3 Global Autoimmune Drugs Sales Price by Manufacturers (2021-2026)
- 4.4 Global Autoimmune Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026
- 4.5 Global Autoimmune Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 4.6 Global Autoimmune Drugs Manufacturers, Product Type & Application
- 4.7 Global Autoimmune Drugs Manufacturers' Establishment Date
- 4.8 Market Competitive Analysis
- 4.8.1 Global Autoimmune Drugs Market CR5 and HHI
- 4.8.2 2025 Autoimmune Drugs Tier 1, Tier 2, and Tier 3
5 Autoimmune Drugs Market by Type
- 5.1 Global Autoimmune Drugs Revenue by Type
- 5.1.1 Global Autoimmune Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 5.1.2 Global Autoimmune Drugs Revenue by Type (2021-2032) & (US$ Million)
- 5.1.3 Global Autoimmune Drugs Revenue Market Share by Type (2021-2032)
- 5.2 Global Autoimmune Drugs Sales by Type
- 5.2.1 Global Autoimmune Drugs Sales by Type (2021 VS 2025 VS 2032)
- 5.2.2 Global Autoimmune Drugs Sales by Type (2021-2032) & (K Units)
- 5.2.3 Global Autoimmune Drugs Sales Market Share by Type (2021-2032)
- 5.3 Global Autoimmune Drugs Price by Type
6 Autoimmune Drugs Market by Application
- 6.1 Global Autoimmune Drugs Revenue by Application
- 6.1.1 Global Autoimmune Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 6.1.2 Global Autoimmune Drugs Revenue by Application (2021-2032) & (US$ Million)
- 6.1.3 Global Autoimmune Drugs Revenue Market Share by Application (2021-2032)
- 6.2 Global Autoimmune Drugs Sales by Application
- 6.2.1 Global Autoimmune Drugs Sales by Application (2021 VS 2025 VS 2032)
- 6.2.2 Global Autoimmune Drugs Sales by Application (2021-2032) & (K Units)
- 6.2.3 Global Autoimmune Drugs Sales Market Share by Application (2021-2032)
- 6.3 Global Autoimmune Drugs Price by Application
7 Company Profiles
- 7.1 Biogen
- 7.1.1 Biogen Company Information
- 7.1.2 Biogen Business Overview
- 7.1.3 Biogen Autoimmune Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.1.4 Biogen Autoimmune Drugs Product Portfolio
- 7.1.5 Biogen Recent Developments
- 7.2 AbbVie
- 7.2.1 AbbVie Company Information
- 7.2.2 AbbVie Business Overview
- 7.2.3 AbbVie Autoimmune Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.2.4 AbbVie Autoimmune Drugs Product Portfolio
- 7.2.5 AbbVie Recent Developments
- 7.3 Amgen
- 7.3.1 Amgen Company Information
- 7.3.2 Amgen Business Overview
- 7.3.3 Amgen Autoimmune Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.3.4 Amgen Autoimmune Drugs Product Portfolio
- 7.3.5 Amgen Recent Developments
- 7.4 Baxter
- 7.4.1 Baxter Company Information
- 7.4.2 Baxter Business Overview
- 7.4.3 Baxter Autoimmune Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.4.4 Baxter Autoimmune Drugs Product Portfolio
- 7.4.5 Baxter Recent Developments
- 7.5 GSK
- 7.5.1 GSK Company Information
- 7.5.2 GSK Business Overview
- 7.5.3 GSK Autoimmune Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.5.4 GSK Autoimmune Drugs Product Portfolio
- 7.5.5 GSK Recent Developments
- 7.6 Pfizer
- 7.6.1 Pfizer Company Information
- 7.6.2 Pfizer Business Overview
- 7.6.3 Pfizer Autoimmune Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.6.4 Pfizer Autoimmune Drugs Product Portfolio
- 7.6.5 Pfizer Recent Developments
- 7.7 Eli Lilly
- 7.7.1 Eli Lilly Company Information
- 7.7.2 Eli Lilly Business Overview
- 7.7.3 Eli Lilly Autoimmune Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.7.4 Eli Lilly Autoimmune Drugs Product Portfolio
- 7.7.5 Eli Lilly Recent Developments
- 7.8 Roche
- 7.8.1 Roche Company Information
- 7.8.2 Roche Business Overview
- 7.8.3 Roche Autoimmune Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.8.4 Roche Autoimmune Drugs Product Portfolio
- 7.8.5 Roche Recent Developments
- 7.9 Johnson & Johnson
- 7.9.1 Johnson & Johnson Company Information
- 7.9.2 Johnson & Johnson Business Overview
- 7.9.3 Johnson & Johnson Autoimmune Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.9.4 Johnson & Johnson Autoimmune Drugs Product Portfolio
- 7.9.5 Johnson & Johnson Recent Developments
8 North America
- 8.1 North America Autoimmune Drugs Market Size by Type
- 8.1.1 North America Autoimmune Drugs Revenue by Type (2021-2032)
- 8.1.2 North America Autoimmune Drugs Sales by Type (2021-2032)
- 8.1.3 North America Autoimmune Drugs Price by Type (2021-2032)
- 8.2 North America Autoimmune Drugs Market Size by Application
- 8.2.1 North America Autoimmune Drugs Revenue by Application (2021-2032)
- 8.2.2 North America Autoimmune Drugs Sales by Application (2021-2032)
- 8.2.3 North America Autoimmune Drugs Price by Application (2021-2032)
- 8.3 North America Autoimmune Drugs Market Size by Country
- 8.3.1 North America Autoimmune Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
- 8.3.2 North America Autoimmune Drugs Sales by Country (2021 VS 2025 VS 2032)
- 8.3.3 North America Autoimmune Drugs Price by Country (2021-2032)
- 8.3.4 United States
- 8.3.5 Canada
9 Europe
- 9.1 Europe Autoimmune Drugs Market Size by Type
- 9.1.1 Europe Autoimmune Drugs Revenue by Type (2021-2032)
- 9.1.2 Europe Autoimmune Drugs Sales by Type (2021-2032)
- 9.1.3 Europe Autoimmune Drugs Price by Type (2021-2032)
- 9.2 Europe Autoimmune Drugs Market Size by Application
- 9.2.1 Europe Autoimmune Drugs Revenue by Application (2021-2032)
- 9.2.2 Europe Autoimmune Drugs Sales by Application (2021-2032)
- 9.2.3 Europe Autoimmune Drugs Price by Application (2021-2032)
- 9.3 Europe Autoimmune Drugs Market Size by Country
- 9.3.1 Europe Autoimmune Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
- 9.3.2 Europe Autoimmune Drugs Sales by Country (2021 VS 2025 VS 2032)
- 9.3.3 Europe Autoimmune Drugs Price by Country (2021-2032)
- 9.3.4 Germany
- 9.3.5 France
- 9.3.6 U.K.
- 9.3.7 Italy
- 9.3.8 Netherlands
10 China
- 10.1 China Autoimmune Drugs Market Size by Type
- 10.1.1 China Autoimmune Drugs Revenue by Type (2021-2032)
- 10.1.2 China Autoimmune Drugs Sales by Type (2021-2032)
- 10.1.3 China Autoimmune Drugs Price by Type (2021-2032)
- 10.2 China Autoimmune Drugs Market Size by Application
- 10.2.1 China Autoimmune Drugs Revenue by Application (2021-2032)
- 10.2.2 China Autoimmune Drugs Sales by Application (2021-2032)
- 10.2.3 China Autoimmune Drugs Price by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Autoimmune Drugs Market Size by Type
- 11.1.1 Asia Autoimmune Drugs Revenue by Type (2021-2032)
- 11.1.2 Asia Autoimmune Drugs Sales by Type (2021-2032)
- 11.1.3 Asia Autoimmune Drugs Price by Type (2021-2032)
- 11.2 Asia Autoimmune Drugs Market Size by Application
- 11.2.1 Asia Autoimmune Drugs Revenue by Application (2021-2032)
- 11.2.2 Asia Autoimmune Drugs Sales by Application (2021-2032)
- 11.2.3 Asia Autoimmune Drugs Price by Application (2021-2032)
- 11.3 Asia Autoimmune Drugs Market Size by Country
- 11.3.1 Asia Autoimmune Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
- 11.3.2 Asia Autoimmune Drugs Sales by Country (2021 VS 2025 VS 2032)
- 11.3.3 Asia Autoimmune Drugs Price by Country (2021-2032)
- 11.3.4 Japan
- 11.3.5 South Korea
- 11.3.6 India
- 11.3.7 Australia
- 11.3.8 Taiwan
- 11.3.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Autoimmune Drugs Market Size by Type
- 12.1.1 SAMEA Autoimmune Drugs Revenue by Type (2021-2032)
- 12.1.2 SAMEA Autoimmune Drugs Sales by Type (2021-2032)
- 12.1.3 SAMEA Autoimmune Drugs Price by Type (2021-2032)
- 12.2 SAMEA Autoimmune Drugs Market Size by Application
- 12.2.1 SAMEA Autoimmune Drugs Revenue by Application (2021-2032)
- 12.2.2 SAMEA Autoimmune Drugs Sales by Application (2021-2032)
- 12.2.3 SAMEA Autoimmune Drugs Price by Application (2021-2032)
- 12.3 SAMEA Autoimmune Drugs Market Size by Country
- 12.3.1 SAMEA Autoimmune Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
- 12.3.2 SAMEA Autoimmune Drugs Sales by Country (2021 VS 2025 VS 2032)
- 12.3.3 SAMEA Autoimmune Drugs Price by Country (2021-2032)
- 12.3.4 Brazil
- 12.3.5 Argentina
- 12.3.6 Chile
- 12.3.7 Colombia
- 12.3.8 Peru
- 12.3.9 Saudi Arabia
- 12.3.10 Israel
- 12.3.11 UAE
- 12.3.12 Turkey
- 12.3.13 Iran
- 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
- 13.1 Autoimmune Drugs Value Chain Analysis
- 13.1.1 Autoimmune Drugs Key Raw Materials
- 13.1.2 Raw Materials Key Suppliers
- 13.1.3 Manufacturing Cost Structure
- 13.1.4 Autoimmune Drugs Production Mode & Process
- 13.2 Autoimmune Drugs Sales Channels Analysis
- 13.2.1 Direct Comparison with Distribution Share
- 13.2.2 Autoimmune Drugs Distributors
- 13.2.3 Autoimmune Drugs Customers
14 Concluding Insights
15 Appendix
- 15.1 Reasons for Doing This Study
- 15.2 Research Methodology
- 15.3 Research Process
- 15.4 Authors List of This Report
- 15.5 Data Source
- 15.5.1 Secondary Sources
- 15.5.2 Primary Sources
- 15.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst